Literature DB >> 1716260

Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects.

D R Clemmons1, D K Snyder, W H Busby.   

Abstract

Insulin-like growth factor binding protein-2 (IGFBP-2) is one of a family of IGFBPs that are present in extracellular fluids, and binds both IGF-II and IGF-I with high affinity. These studies were conducted to determine the nutritional and hormonal variables that regulate plasma IGFBP-2 concentrations in humans. The mean plasma IGFBP-2 concentration for 38 normal adult subjects was 150 +/- 61 micrograms/L and was 4.7-fold greater than their mean fasting IGFBP-1 value. Mean IGFBP-2 values in cord sera of 26 normal term infants was 3.8-fold greater than the normal adult mean value. Likewise, the mean value for 44 hypopituitary adults was increased 2-fold compared to normal. There was no suppression of IGFBP-2 values in acromegaly. Normal adult subjects showed minimal fluctuations (less than 2-fold changes) in plasma IGFBP-2 concentrations during a 48-h sampling period. These changes were significantly less than the changes that occurred in plasma IGFBP-1 during the same interval. Plasma IGFBP-2 did not change significantly post prandially or after a glucose infusion. Extreme insulin deficiency, after 9 days of fasting, was associated with a 1.7-fold increase in plasma IGFBP-2. Administration of GH, which is known to cause a major decrease in plasma IGFBP-1 and in IGFBP-2 in hypophysectomized animals, did not result in a change in calorically restricted normal adult subjects, suggesting that a normal caloric intake is required for GH to suppress IGFBP-2. In summary, these results show that plasma IGFBP-2 is regulated differently than IGFBP-1. Acute stimulation of insulin secretion does not suppress IGFBP-2, and there is much less daily fluctuation compared to IGFBP-1. These findings suggest that plasma IGFBP-2 levels are more stable than IGFBP-1, and therefore IGFBP-2 may serve as a larger reservior that is available for IGF transport.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1716260     DOI: 10.1210/jcem-73-4-727

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

1.  Molecular identification of grass carp igfbp2 and the effect of glucose, insulin, and glucagon on igfbp2 mRNA expression.

Authors:  Guokun Yang; Wenli Zhao; Chaobin Qin; Liping Yang; Xiaolin Meng; Ronghua Lu; Xiao Yan; Xianglin Cao; Yanmin Zhang; Guoxing Nie
Journal:  Fish Physiol Biochem       Date:  2020-04-23       Impact factor: 2.794

2.  Skeletal muscle mass is associated with bone geometry and microstructure and serum insulin-like growth factor binding protein-2 levels in adult women and men.

Authors:  Nathan K Lebrasseur; Sara J Achenbach; L Joseph Melton; Shreyasee Amin; Sundeep Khosla
Journal:  J Bone Miner Res       Date:  2012-10       Impact factor: 6.741

Review 3.  Defining the pathway to insulin-like growth factor system targeting in cancer.

Authors:  Steven A Rosenzweig; Hanudatta S Atreya
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

4.  Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults.

Authors:  S Khosla; A A Hassoun; B K Baker; F Liu; N N Zein; M P Whyte; C A Reasner; T B Nippoldt; R D Tiegs; R L Hintz; C A Conover
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

Review 5.  IGF-I/IGFBP system: metabolism outline and physical exercise.

Authors:  R Gatti; E F De Palo; G Antonelli; P Spinella
Journal:  J Endocrinol Invest       Date:  2012-06-18       Impact factor: 4.256

Review 6.  The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes.

Authors:  Swapnil N Rajpathak; Marc J Gunter; Judith Wylie-Rosett; Gloria Y F Ho; Robert C Kaplan; Radhika Muzumdar; Thomas E Rohan; Howard D Strickler
Journal:  Diabetes Metab Res Rev       Date:  2009-01       Impact factor: 4.876

Review 7.  Colorectal cancer biomarkers: to be or not to be? Cautionary tales from a road well travelled.

Authors:  Kim Y C Fung; Edouard Nice; Ilka Priebe; Damien Belobrajdic; Aloke Phatak; Leanne Purins; Bruce Tabor; Celine Pompeia; Trevor Lockett; Timothy E Adams; Antony Burgess; Leah Cosgrove
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

Review 8.  Growth hormone, insulin-like growth factors, and the skeleton.

Authors:  Andrea Giustina; Gherardo Mazziotti; Ernesto Canalis
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

9.  The effect of GH therapy on the immunoreactive forms and distribution of IGFBP-3, IGF-I, the acid-labile subunit, and growth rate in GH-deficient children.

Authors:  S H Mandel; E Moreland; R G Rosenfeld; S E Gargosky
Journal:  Endocrine       Date:  1997-12       Impact factor: 3.633

Review 10.  Insulin resistance and hyperinsulinaemia in the development and progression of cancer.

Authors:  Ian F Godsland
Journal:  Clin Sci (Lond)       Date:  2009-11-23       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.